Andrew Sinclair is Director at SOLENO THERAPEUTICS INC (SLNO). They have made 5 open-market trades across 3 companies since 2018, most recently 2025-06-11.
CIK 0001762451
5 open-market purchases totalling $39.8M since 2018, never a sale. Across 5 scored buys the stock is up 40.2% at ninety days, and 38.8 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 60% |
| Avg Move | +1.4% | +1.4% | +40.2% |
| Alpha | +0.3% | -1.0% | +38.8% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRRA | BUY | 2022-01-31 | 2022-02-01 | $27.00 | $4.0M | +4.2% | +4.9% | +82.3% |
| ACET | BUY | 2021-12-08 | 2021-12-13 | $14.00 | $7.0M | +7.8% | +1.0% | -16.8% |
| SLNO | BUY | 2020-06-26 | 2020-07-06 | $1.65 | $11.0M | -8.5% | -15.5% | -3.8% |
| SLNO | BUY | 2019-10-25 | 2019-10-29 | $1.20 | $2.8M | -8.4% | +12.3% | +114.3% |
| SLNO | BUY | 2018-12-21 | 2018-12-27 | $1.60 | $14.9M | +11.7% | +4.3% | +25.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.